Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Short-term Investments (2016 - 2022)

Historic Short-term Investments for Cartesian Therapeutics (RNAC) over the last 8 years, with Q4 2022 value amounting to $28.2 million.

  • Cartesian Therapeutics' Short-term Investments rose 10120.02% to $28.2 million in Q4 2022 from the same period last year, while for Dec 2022 it was $28.2 million, marking a year-over-year increase of 10120.02%. This contributed to the annual value of $28.2 million for FY2022, which is 10120.02% up from last year.
  • Latest data reveals that Cartesian Therapeutics reported Short-term Investments of $28.2 million as of Q4 2022, which was up 10120.02% from $33.6 million recorded in Q3 2022.
  • Cartesian Therapeutics' Short-term Investments' 5-year high stood at $33.6 million during Q3 2022, with a 5-year trough of $278000.0 in Q2 2020.
  • In the last 5 years, Cartesian Therapeutics' Short-term Investments had a median value of $14.0 million in 2021 and averaged $14.3 million.
  • As far as peak fluctuations go, Cartesian Therapeutics' Short-term Investments tumbled by 9828.24% in 2020, and later soared by 867302.16% in 2021.
  • Quarter analysis of 5 years shows Cartesian Therapeutics' Short-term Investments stood at $6.0 million in 2018, then plummeted by 95.34% to $279000.0 in 2019, then dropped by 0.36% to $278000.0 in 2020, then soared by 4935.25% to $14.0 million in 2021, then soared by 101.2% to $28.2 million in 2022.
  • Its Short-term Investments was $28.2 million in Q4 2022, compared to $33.6 million in Q3 2022 and $4.0 million in Q2 2022.